Cynomolgus Monkey BMSC & CD34+ HSCs: Essential Tools for Regenerative Medicine & Gene Therapy

Keywords

Cynomolgus monkey BMSC, cynomolgus monkey CD34+ HPSC, Cynomolgus monkey bone marrow mesenchymal stromal cells, cynomolgus monkey CD34+ hematopoietic stem cells, non-human primate stem cells, regenerative medicine research, tissue engineering, hematopoietic reconstitution, stem cell transplantation, gene therapy preclinical models, cell therapy development

IPHASE Products

Introduction

Non-human primates, especially cynomolgus monkeys, share over 93% genetic homology with humans, with highly similar physiological structures, immune systems and disease progression patterns. They are the most widely accepted and reliable preclinical models for bridging the gap between laboratory research and clinical application in cell therapy and gene therapy.

Among all NHP-derived biological materials, bone marrow-derived stem cells are the most widely used and well-characterized cell populations, the two most important and widely used cell populations are cynomolgus monkey bone marrow mesenchymal stromal cells and Cynomolgus monkey CD34+ hematopoietic stem cells.

What is cynomolgus monkey bone marrow mesenchymal stromal cells (BMSC)?

Cynomolgus monkey bone marrow mesenchymal stromal cells (BMSCs) are multipotent stromal cells derived from the bone marrow of cynomolgus macaques. These cells are known for their ability to adhere to plastic, expand in culture, and differentiate into several mesenchymal lineages, such as osteoblasts, adipocytes, and chondrocytes under appropriate conditions. Because of their supportive role in the bone marrow microenvironment, cynomolgus monkey BMSCs are widely used in regenerative medicine, tissue engineering, immunology, and translational research, providing a useful non-human primate model for studying cell growth, differentiation, and therapeutic development.

What is cynomolgus monkey bone marrow CD34+ hematopoietic stem/progenitor cells (HSPC)?

Cynomolgus monkey bone marrow CD34+ hematopoietic stem/progenitor cells (HSPCs) are immature blood-forming cells isolated from the bone marrow of cynomolgus macaques. They express the CD34 surface marker, which is commonly used to identify stem and early progenitor populations with the ability to self-renew and differentiate into multiple blood cell lineages, including red blood cells, white blood cells, and platelets. As a non-human primate cell source, cynomolgus monkey CD34+ HSPCs are widely used in hematology, stem cell biology, gene therapy, and transplantation research, where they serve as a valuable model for studying hematopoiesis, immune reconstitution, and cell-based therapeutic applications.

Key Differences

While both originate from cynomolgus monkey bone marrow, these two stem cell populations have distinct differentiation potentials and functional roles, making them suitable for different research applications:

Applications

1. Regenerative Medicine & Tissue Engineering

• Cynomolgus monkey BM-MSCs are the most widely used seed cells for regenerative medicine, thanks to their strong proliferation, low immunogenicity and multi-lineage differentiation potential:
• Musculoskeletal repair: Develop cell therapies for osteoarthritis, cartilage defects and bone fractures; BMSC transplantation significantly promotes cartilage regeneration and improves joint function.
• Cardiovascular regeneration: Evaluate efficacy for myocardial infarction and heart failure; cells differentiate into cardiomyocytes and secrete angiogenic factors to enhance myocardial perfusion.
• Neurological treatment: Used in preclinical research of spinal cord injury, stroke and neurodegenerative diseases; reduce neuroinflammation and support neural tissue repair.
• Wound healing & fibrosis: Study therapeutic effects on chronic wounds, liver and pulmonary fibrosis to support clinical translation.

2. Hematopoietic Reconstitution & Stem Cell Transplantation

• Cynomolgus monkey CD34+ HSPCs are the most trusted primary tool for studying hematopoietic stem cell transplantation，the only curative therapy for many blood cancers and genetic blood disorders:
• HSCT protocol optimization: Test different conditioning regimens, cell doses and delivery routes to improve engraftment efficiency and reduce complications like graft-versus-host disease .
• Cord blood and haploidentical transplantation: Develop in vitro expansion methods to boost engraftment of limited cord blood units, addressing the global shortage of matched donors.
• Long-term safety evaluation: Monitor sustained hematopoietic reconstitution and potential tumorigenicity in monkeys, providing critical safety data for human clinical trials.

3. Gene Therapy Research

• Both BMSCs and CD34+ HSPCs are ideal target cells for ex vivo gene therapy, a transformative treatment for genetic diseases and cancer:
• CD34+ HSPC based gene therapy: The most clinically advanced platform; validate CRISPR-Cas9 gene editing and viral vector delivery for genetic blood diseases.
• BMSC based gene therapy: Use as cellular vehicles to deliver therapeutic genes directly to damaged tissues; evaluate safety, biodistribution and long-term efficacy for degenerative diseases and cancer.
• Immunotherapy development: Generate gene-modified CAR-T/CAR-NK cells from CD34+ HSPCs to assess antitumor activity and off-target effects in preclinical monkey models.

Conclusion

Cynomolgus monkey BMSCs and CD34+ hematopoietic stem cells are indispensable tools for advancing regenerative medicine, tissue engineering and gene therapy research. Their high similarity to human stem cells ensures that preclinical results obtained in cynomolgus monkey models have the highest translational value to human clinical trials.

IPHASE provides high quality, well-characterized cynomolgus monkey stem cell products with strict batch consistency and full regulatory compliance. Whether you are developing novel cell therapies, optimizing transplantation protocols or validating gene editing technologies, our products can support your research from early discovery to preclinical IND submission.

FAQs

1. What is the difference between cynomolgus monkey BMSCs and CD34+ HSPCs?

BM-MSCs are mesenchymal lineage stem cells with multi-lineage differentiation and immunomodulatory functions, mainly used for tissue repair. CD34+ HSPCs are hematopoietic lineage stem cells that can reconstitute the entire blood and immune system, mainly used for transplantation and gene therapy.

2. Why use cynomolgus monkey stem cells instead of mouse or human stem cells?

Cynomolgus monkeys share higher genetic and physiological similarity with humans than rodents, providing more predictive preclinical data. They also avoid the ethical issues associated with using human embryonic stem cells.

3. What technical support do you provide after purchase?

IPHASE provide comprehensive technical support including detailed cell culture protocols, troubleshooting guidance, and one-on-one consultation with our scientific team. We can also assist with experimental design and data interpretation upon request.